We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.07B
AUM Growth
-$429M
Cap. Flow
+$142M
Cap. Flow %
6.88%
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$137M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$48.1M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$32.9M
4
RPTX
Repare Therapeutics
RPTX
+$28.7M
5
CGEM icon
Cullinan Oncology
CGEM
+$24.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$99.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$64.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$37.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$14.6M
5
GBIO
Generation Bio
GBIO
+$8.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACIU icon
26
AC Immune
ACIU
$241M
$26.8M 1.3%
7,428,379
– –
LXRX icon
27
Lexicon Pharmaceuticals
LXRX
$1.04B
$26.3M 1.27%
14,149,179
-207,410
-1% -$396K
VSTM icon
28
Verastem
VSTM
$536M
$23.2M 1.12%
1,664,555
– –
PNT
29
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$22.9M 1.11%
3,367,826
– –
NUVL
30
DELISTED
Nuvalent
NUVL
$22.6M 1.09%
1,666,282
+976,864
+142% +$10.3M
COGT icon
31
Cogent Biosciences
COGT
$7.07B
$20.4M 0.98%
2,257,174
+724,892
+47% +$4.95M
VRDN icon
32
Viridian Therapeutics
VRDN
$2.2B
$20.2M 0.97%
1,744,012
– –
RAIN
33
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$19.6M 0.95%
3,526,729
– –
STRO icon
34
Sutro Biopharma
STRO
$411M
$18M 0.87%
344,795
– –
JANX icon
35
Janux Therapeutics
JANX
$950M
$18M 0.87%
1,470,334
+327,994
+29% +$3.88M
TYRA icon
36
Tyra Biosciences
TYRA
$1.97B
$17.7M 0.85%
2,472,327
– –
REPL icon
37
Replimune Group
REPL
$16.2M 0.78%
926,529
– –
CNCE
38
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$15.3M 0.74%
3,629,000
+1,376,000
+61% +$5.44M
OVID icon
39
Ovid Therapeutics
OVID
$442M
$14.7M 0.71%
6,851,051
– –
ANNX icon
40
Annexon
ANNX
$863M
$14.3M 0.69%
+3,780,694
New +$11.6M
VIRX
41
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$14M 0.68%
3,614,662
– –
CALT
42
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.5M 0.65%
750,000
– –
ETNB
43
DELISTED
89bio
ETNB
$12.6M 0.61%
+3,898,000
New +$11.8M
ANTX icon
44
AN2 Therapeutics
ANTX
$192M
$12.5M 0.61%
1,616,665
– –
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$12.2M 0.59%
49,654
– –
EPIX
46
DELISTED
ESSA Pharma
EPIX
$11.7M 0.56%
3,698,629
+3,000
+0.1% +$16.8K
IMA
47
ImageneBio Inc
IMA
$67.2M
$11.1M 0.54%
208,589
+125
+0.1% +$6.9K
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.9M 0.52%
1,275,240
-314,255
-20% -$2.71M
WHWK
49
Whitehawk Therapeutics
WHWK
$190M
$10.8M 0.52%
879,085
– –
CTMX icon
50
CytomX Therapeutics
CTMX
$714M
$10.6M 0.51%
5,803,700
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2022 Portfolio in Review

As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.

  • BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
  • BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
  • BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
  • BVF Inc fully exited argenx in Q2 2022, selling an estimated $99.7M.
  • BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q2 2022.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.